Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials
Tolerogenic dendritic cells (tolDCs) have reached patients with autoimmune and inflammatory disease, at least in clinical trials. The safety of tolDCs as intervention therapy has been established, but the capacity to modulate autoimmune response in vivo remains to be demonstrated. Studies have revea...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01598/full |
| _version_ | 1818929470599331840 |
|---|---|
| author | Jessica S. Suwandi Tatjana Nikolic Bart O. Roep Bart O. Roep |
| author_facet | Jessica S. Suwandi Tatjana Nikolic Bart O. Roep Bart O. Roep |
| author_sort | Jessica S. Suwandi |
| collection | DOAJ |
| description | Tolerogenic dendritic cells (tolDCs) have reached patients with autoimmune and inflammatory disease, at least in clinical trials. The safety of tolDCs as intervention therapy has been established, but the capacity to modulate autoimmune response in vivo remains to be demonstrated. Studies have revealed a diversity of regulatory mechanisms that tolDCs may employ in vivo. These mechanisms differ between various types of modulated tolDC. The most often foreseen action of tolDCs is through regulatory polarization of naïve T cells or activation of existing regulatory T cells, which should ultimately diminish autoimmune inflammation. Yet, selection of a target autoantigen remains critical to expedite tissue specific tolerance induction, while measuring immune modulation incited by tolDCs in vivo provides a great challenge. We will discuss the regulatory action of different types of tolDCs and the possible methods to monitor immunological efficacy endpoints for the next generation clinical trials. |
| first_indexed | 2024-12-20T03:45:19Z |
| format | Article |
| id | doaj.art-100e5db2fccc4a919df510243ca31189 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T03:45:19Z |
| publishDate | 2017-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-100e5db2fccc4a919df510243ca311892022-12-21T19:54:37ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-11-01810.3389/fimmu.2017.01598314262Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical TrialsJessica S. Suwandi0Tatjana Nikolic1Bart O. Roep2Bart O. Roep3Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, NetherlandsDepartment of Diabetes Immunology, Diabetes & Metabolism Research Institute, Beckman Research Institute, City of Hope, Duarte, CA, United StatesTolerogenic dendritic cells (tolDCs) have reached patients with autoimmune and inflammatory disease, at least in clinical trials. The safety of tolDCs as intervention therapy has been established, but the capacity to modulate autoimmune response in vivo remains to be demonstrated. Studies have revealed a diversity of regulatory mechanisms that tolDCs may employ in vivo. These mechanisms differ between various types of modulated tolDC. The most often foreseen action of tolDCs is through regulatory polarization of naïve T cells or activation of existing regulatory T cells, which should ultimately diminish autoimmune inflammation. Yet, selection of a target autoantigen remains critical to expedite tissue specific tolerance induction, while measuring immune modulation incited by tolDCs in vivo provides a great challenge. We will discuss the regulatory action of different types of tolDCs and the possible methods to monitor immunological efficacy endpoints for the next generation clinical trials.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01598/fulltolerogenic dendritic cellsmonitoring endpointsclinical trialsautoimmune diseasesregulatory actionantigen specific |
| spellingShingle | Jessica S. Suwandi Tatjana Nikolic Bart O. Roep Bart O. Roep Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials Frontiers in Immunology tolerogenic dendritic cells monitoring endpoints clinical trials autoimmune diseases regulatory action antigen specific |
| title | Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials |
| title_full | Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials |
| title_fullStr | Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials |
| title_full_unstemmed | Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials |
| title_short | Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials |
| title_sort | translating mechanism of regulatory action of tolerogenic dendritic cells to monitoring endpoints in clinical trials |
| topic | tolerogenic dendritic cells monitoring endpoints clinical trials autoimmune diseases regulatory action antigen specific |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01598/full |
| work_keys_str_mv | AT jessicassuwandi translatingmechanismofregulatoryactionoftolerogenicdendriticcellstomonitoringendpointsinclinicaltrials AT tatjananikolic translatingmechanismofregulatoryactionoftolerogenicdendriticcellstomonitoringendpointsinclinicaltrials AT bartoroep translatingmechanismofregulatoryactionoftolerogenicdendriticcellstomonitoringendpointsinclinicaltrials AT bartoroep translatingmechanismofregulatoryactionoftolerogenicdendriticcellstomonitoringendpointsinclinicaltrials |